Status:
COMPLETED
Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics
Lead Sponsor:
Incyte Corporation
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.
Eligibility Criteria
Inclusion
- Established diagnosis of Type 2 Diabetes
- Stable dose of metformin for more than 8 weeks
Exclusion
- Subjects with Addison's disease or Cushing's Syndrome
- Type 1 diabetes mellitus or secondary forms of diabetes
- Subjects with uncontrolled thyroid disease
- History of renal impairment
Key Trial Info
Start Date :
May 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT00698230
Start Date
May 1 2008
End Date
May 1 2009
Last Update
February 14 2018
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35242
2
Artesia, California, United States
3
Calabasas, California, United States, 91307
4
Fresno, California, United States, 93720